ライフサイエンスコーパス: phase III

1 ging, and attendant fires and fragmentation (phase III).

2 0.5Mn1.5Ni0.5O4 (Phase II) and Mn1.5Ni0.5O4 (Phase III).

3 velation of the mysterious structure of blue phase III.

4 ere stress occurred during the first part of phase III.

5 optical, and photonic devices based on blue phase III.

6 data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,9

7 We performed a meta-analysis of the 4 phase III AF trials of the currently available NOACs ver

8 The phase III ALLY-3+ study (N = 50) evaluated DCV-SOF with

9 imary motor cortex and precerebellar nuclei (phase III) and finally visual cortex in the most severe

10 ous, one-dimensional (1D) polymer at 20 GPa (Phase III); and an extended 3D network above ~35 GPa (Ph

11 ween no boost and a 16-Gy boost in the EORTC phase III "boost no boost" trial (1989-1996).

12 tured polymer scaffold of the amorphous blue phase III (BPIII) of cholesteric liquid crystals (LCs),

13 ctive of the randomized, placebo-controlled, phase III C-EDGE IBLD study was to assess the safety and

14 ugs (HAP) have been developed, including the phase III candidate TH-302 (evofosfamide) and the precli

15 nd provide an overview of recently published phase III cardiovascular trials using primary composite

16 ign concept that led to the discovery of the phase III clinical candidate deleobuvir (BI 207127).

17 Phase III clinical studies in CRPC patients are schedule

18 ients, but these are underrepresented in the phase III clinical studies that established the current

19 the only vaccine platform that has completed Phase III clinical studies, it is imperative to gain a b

20 support progression to evaluation in larger phase III clinical studies.

21 myocardial salvage index, indicating that a phase III clinical trial assessing intracoronary nitrite

22 ntegration of molecular targeted agents into phase III clinical trial design has lagged in the curati

23 In a prospective, randomized phase III clinical trial evaluating the activity of tras

24 against HIV infection observed in the RV144 phase III clinical trial highlighted the need for furthe

25 adipine is currently undergoing testing in a phase III clinical trial in early PD.

26 2i epitope." IMPORTANCE: Data from the RV144 phase III clinical trial suggested that the presence of

27 antisepsis agent to successfully complete a phase III clinical trial was human recumbent activated p

28 ization protocol mimicking that of the RV144 phase III clinical trial was used.

29 As part of this phase III clinical trial, a central pathologist evaluate

30 te therapeutic benefit against melanoma in a phase III clinical trial.

31 ested as a neuroprotective agent for PD in a phase III clinical trial.

32 provides strong rationale for a confirmatory phase III clinical trial.

33 0) and from Gynecologic Oncology Group (GOG) phase III clinical trials 218 (n = 788) and 262 (n = 557

34 tematic literature review and identified two phase III clinical trials and a randomized phase II dose

35 than that of (-)-epigallocatechin gallate in Phase III clinical trials and about one order of magnitu

36 Phase III clinical trials are now underway examining the

37 Phase III clinical trials evaluating bevacizumab (an ant

38 ibitors are emerging as anti-cancer drugs in phase III clinical trials for BRCA-deficient tumors.

39 most robust evidence from large phase II and phase III clinical trials for ranibizumab demonstrated v

40 al agonist of hGPR40 receptor, which reached phase III clinical trials for the potential treatment of

41 Four phase III clinical trials form the primary evidence base

42 Results from phase III clinical trials in adults and phase II clinica

43 inhibitor in clinical testing, with ongoing phase III clinical trials in patients with chronic lymph

44 Data from two phase III clinical trials of omalizumab in patients with

45 complete rotavirus genomes collected during phase III clinical trials of RotaTeqTM in Sub-Saharan Af

46 SVR at various post-treatment time points in phase III clinical trials of sofosbuvir (SOF)-containing

47 Among the phase III clinical trials only the RV144 vaccine trial e

48 ation acute coronary syndrome enrolled in 11 phase III clinical trials over 17 years (1994-2010).

49 Phase III clinical trials showing a survival advantage i

50 Nonetheless, phase III clinical trials that have attempted to antagon

51 nt development stages, from the lab bench to phase III clinical trials to clinical practice.

52 f patients with metastatic CRC (mCRC) of two phase III clinical trials, CAIRO and CAIRO2.

53 clinical testing and has progressed through phase III clinical trials, continued efforts are underwa

54 el-targeted TNFalpha derivative currently in phase III clinical trials, substituted for Y-redirected

55 nt treatments for micrometastatic disease in phase III clinical trials.

56 fficacy against EBOV infections in humans in phase III clinical trials.

57 argeting HCMV terminase that is currently in phase III clinical trials.

58 pecially with phage therapy advancing toward phase III clinical trials.

59 by positive results from recently completed phase III clinical trials.

60 remain, these trials hold promise for future phase III clinical trials.

61 a poxvirus-based cancer vaccine currently in phase III clinical trials.

62 ed many Met inhibitors, some of which are in phase III clinical trials.

63 linical models, most therapies still fail in phase III clinical trials.

64 difficult course with 3 compounds failing in phase III clinical trials.

65 In Europe, ferumoxtran-10 is entering phase III clinical trials.

66 ide in Diabetic Macular Edema (FAME) A and B Phase III clinical trials.

67 , a prodrug of which is currently undergoing phase III clinical trials.

68 trial predicting an effective or ineffective phase III conclusion, by prediction error, and by concor

69 10), intragastric DB switched the origin of phase III contractions from the stomach to the duodenum

70 Motilin-induced phase III contractions have been identified as a hunger

71 Motilin-induced phase III contractions induced hunger feelings through a

72 These phase III contractions occur as part of the migrating mo

73 The impact of pharmacologically induced phase III contractions on the occurrence of hunger peaks

74 peaks and their significant association with phase III contractions was confirmed (P < 0.0001).

75 The association with phase III contractions was studied in 14 healthy volunte

76 Pharmacologically induced phase III contractions were also significantly associate

77 rrence of hunger peaks and their relation to phase III contractions, 2) evaluate whether this relatio

78 The phase III CRYSTAL study demonstrated that addition of ce

79 We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-N

80 was performed using the 1000 Genomes Project Phase III dataset as reference panel.

81 trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a

82 ibitors, anacetrapib and evacetrapib, are in phase III development, and we attempt to differentiate t

83 In phase III, diagnostic test-therapeutic randomized clinic

84 national Group (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled

85 A phase III, double-blind, masked, controlled, multicenter

86 In X-ACT, a phase III, double-blind, placebo-controlled study, CSU p

87 In this phase III, double-blind, placebo-controlled trial, patie

88 n expression for all targets of marketed and phase III drugs across a diverse collection of normal hu

89 idate, describing the steps from research to phase III efficacy studies.

90 umatic brain injury and the feasibility of a Phase III efficacy study.

91 ion, (II) R phase transformation from parent phase, (III) elastic deformation of reoriented martensit

92 event profile was consistent with that from phase III enzalutamide trials.

93 ocarcinoma treated within the international, phase III, European Study Group for Pancreatic Cancer-3

94 waits prospective confirmation in the larger phase III FALCON (Fulvestrant and Anastrozole Compared i

95 n, with a water drop sitting on an oil ring (phase III), finalizing the phase inversion.

96 perties of the practically unobservable blue phase III have eluded scientists for more than a century

97 ric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the

98 stress occurred during the first 40 days of phase III, increasing sugar accumulation, promoted by th

99 CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation Af

100 hemoradiotherapy arm of the RTOG-9501 trial (Phase III Intergroup Trial of Surgery Followed by Radiot

101 This prospective, randomized phase III intergroup trial of the Gynecologic Oncology G

102 In a pooled analysis of three phase III IPF clinical trials, patients receiving pirfen

103 over 52 weeks using data derived from three phase III IPF clinical trials.

104 G+T340 is being investigated further in the phase III MAESTRO study (NCT01746979).

105 In the phase III MAGELLAN (Multicenter, rAndomized, parallel Gr

106 (1) PANCREOX was a phase III multicenter trial to evaluate the benefit of F

107 In this phase III, multicenter, double-blind, placebo-controlled

108 Methods GRECCAR6 was a phase III, multicenter, randomized, open-label, parallel

109 The distribution of enrollment by age in phase III non-ST-segment-elevation acute coronary syndro

110 ective, randomized, multicenter, open-label, phase III noninferiority trial.

111 Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one

112 The phase III North American Intergroup E2496 Trial (Combina

113 The amorphous blue phase III of cholesteric liquid crystals, also known as

114 FENO, FEV1, and the slope of phase III of the single-breath washout test (S) of He (S

115 In a phase III, open-label, comparative, noninferiority study

116 sex-specific meta-analysis was conducted of phase III or IV randomized trials of potent P2Y12 inhibi

117 s the clinical utility of metrics to predict phase III outcomes from simulated phase II trials.

118 The confirmatory phase III part of the study is ongoing.

119 Nevertheless, the phase III part was canceled because of the unreliability

120 enchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying a

121 We obtained individual participant data from phase III placebo-controlled RCTs of therapies for PAH s

122 We performed a post hoc analysis of a phase III placebo-controlled study to identify character

123 In the phase III PlanB trial, RS was prospectively used to defi

124 Phase III prospective, multicenter, randomized clinical

125 r data, we have designed a cooperative group phase III prospective, randomized trial of conventional

126 t radiation therapy (RT) in the context of a phase III randomized clinical trial involving localized,

127 Post hoc analysis from a phase III randomized controlled trial comparing nCRT and

128 A phase III randomized controlled trial demonstrated that

129 re review to identify all publicly available phase III randomized controlled trial evidence.

130 Recent Data Six phase III randomized controlled trials and expert consen

131 ese encouraging results suggest that larger, phase III randomized controlled trials are in order to c

132 Phase III randomized controlled trials of systemic thera

133 We conducted electronic database searches of phase III randomized controlled trials.

134 this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negativ

135 ancer Institute of Canada SR2 (CAN-NCIC-SR2: Phase III Randomized Study of Pre- vs Postoperative Radi

136 This phase III randomized trial compared eribulin with capeci

137 To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in pat

138 A Phase III randomized trial to assess impact on neurologi

139 Patients and Methods In this phase III randomized trial, we assessed the noninferiori

140 ember 2005 and November 2009 in the PETACC-8 phase III randomized trial.Mismatch repair, BRAF V600E,

141 on sensitivity to standard therapies in two phase III randomized trials that represent the developme

142 These data have provided the basis for the phase III randomized, multicenter trial ENDEAVOR.

143 ndividual patient data was pooled from three phase III randomized, placebo-controlled studies of pirf

144 A phase III randomized, placebo-controlled, double-blind c

145 We report the results of a multicenter, phase III, randomized open-label trial exploring the ben

146 X-ACT was a phase III, randomized, double-blind study conducted in 2

147 This was a phase III, randomized, double-blind, multicenter study t

148 Data were pooled from two phase III, randomized, double-blind, placebo-controlled

149 Twelve-week, phase III, randomized, double-masked, multicenter, place

150 This phase III, randomized, placebo (saline)-controlled study

151 Post hoc analysis of the phase III RIDE and RISE studies of ranibizumab for treat

152 nt and warrants further investigation in the phase III setting.

153 safety results in mRCC support study in the phase III setting.

154 rtib, Estybon], a styryl benzylsulfone, is a phase III stage anticancer agent.

155 have been shown to provide benefit in IBD in phase III studies by blocking other antiinflammatory pat

156 Recently reported, placebo-controlled phase III studies demonstrate a meaningful progression-f

157 Data from phase III studies demonstrate that with SOF-based regime

158 CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS

159 Recent clinical evidence from phase III studies has shown that nintedanib has signific

160 l compared with docetaxel in two independent phase III studies in previously treated patients with ad

161 Phase III studies support chemoimmunotherapy as the init

162 Following completion of phase III studies, eventual new drug application approva

163 but are frequently followed by unsuccessful phase III studies, highlighting a disconnect in the tran

164 In phase III studies, treatment with the once-daily fixed-d

165 the efficacy of LDV/SOF regimens in the ION phase III studies.

166 ter transfer protein inhibitors are still in phase III studies.

167 This phase III study (ALLY-3) evaluated the 12-week regimen o

168 A global phase III study (NCT02312206) has been initiated.

169 OG 8802, 9506, 9706, 9906, and 0233) and one phase III study (RTOG 8903).

170 rongly influenced by results of a randomized phase III study among recurrent patients as well as furt

171 We aimed to confirm these results in a phase III study and investigated a potential clinical be

172 Purpose A phase III study comparing eribulin with dacarbazine in p

173 ods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group syst

174 s and Methods This randomized, double-blind, phase III study enrolled patients with histologically co

175 This placebo-controlled phase III study evaluated telotristat ethyl in this sett

176 We report the results of OPUS-2, a phase III study evaluating the efficacy and safety of li

177 eport the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of li

178 pancreatic NET, the longest OS reported in a phase III study for this population.

179 oGRession in Multiple SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosi

180 VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with

181 A recent randomized phase III study of 719 de novo liver transplant recipien

182 In a post hoc analysis of data from a phase III study of the effects of teduglutide on patient

183 e recently published results of a randomized phase III study prompted an update of this guideline.

184 The CONKO-003 phase III study reported a survival benefit with second-

185 A randomized, open-label, phase III study was conducted in 16 institutions through

186 This phase III study was conducted to confirm the phase II re

187 In this phase III study, eribulin was not shown to be superior t

188 The IELSG-19 phase III study, to our knowledge, was the first such st

189 Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of ea

190 apecitabine were included in this randomized phase III study.

191 ngoing IFM/Dana-Farber Cancer Institute 2009 phase III study.

192 TISSE was a randomized, open-label, adaptive phase III study.

193 oposes ideas for further improvement in blue phase III technology to make it feasible for commerciali

194 We performed a randomized phase III trial assessing dose intensification.

195 The NCIC CTG PR3/MRC PR07 randomized phase III trial compared androgen-deprivation therapy (A

196 This blinded phase III trial compared cabozantinib with prednisone in

197 This randomized phase III trial compared lenalidomide as maintenance the

198 This phase III trial compared the safety and efficacy of amru

199 ated in an ongoing international, randomized phase III trial comparing alisertib with investigator's

200 10, the patient was enrolled in a randomized phase III trial comparing different lenalidomide-based t

201 prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define

202 randomized, double-blind, placebo-controlled phase III trial conducted in 12 European countries inclu

203 This open-label phase III trial evaluated efficacy and tolerability of l

204 ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to

205 ndomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment

206 This prospective, randomized phase III trial examined the effect of prophylactic trea

207 mor, and only four randomized trials and one phase III trial have been completed so far, all in the f

208 thout a leukotriene receptor antagonist in a phase III trial in adolescent patients with moderate sym

209 In this randomized, controlled phase III trial in patients with vasopressor-dependent d

210 same domains that had at least one completed phase III trial in the same time frame, but failed to re

211 Methods This randomized, double-blind, phase III trial included AI-treated postmenopausal women

212 A randomized phase III trial is under way, comparing BV+CHP with CHOP

213 Data from a phase III trial of 1,050 patients with mCRPC were used (

214 1, a multinational, randomized, double-blind phase III trial of abiraterone acetate plus prednisone v

215 ernational, open-label randomized controlled phase III trial of adjuvant combination chemotherapy com

216 resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic

217 and target population were identified for a phase III trial of IMGN853 monotherapy in patients with

218 y assigned 1:1 in a multicenter, open-label, phase III trial of letrozole (2.5 mg orally per day) wit

219 ction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemother

220 or more controller medications, in the first phase III trial of tiotropium in children with severe sy

221 A separate phase III trial served as an independent validation set.

222 pective, multicenter, open-label, randomized phase III trial that compared a busulfan-based RIC with

223 ng Patients With Melanoma) was an Intergroup phase III trial that enrolled high-risk patients (stage

224 address this point, we designed a randomized phase III trial to compare rituximab plus cyclophosphami

225 center study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazin

226 We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovi

227 AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab w

228 Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetux

229 hemotherapy and TME (PROSPECT), a randomized phase III trial to validate this experience, is now open

230 ng results in phase II studies, a randomized phase III trial was designed to assess the efficacy of a

231 CPP FAP-310, a randomized, double-blind, Phase III trial was designed to examine the safety and e

232 The goal of this phase III trial was to determine whether IC before chemo

233 lacebo-controlled, randomized, multinational phase III trial, 1,144 patients with human epidermal gro

234 and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal bre

235 ompliant secondary analysis of a prospective phase III trial, adult patients with digital CT images a

236 specimens collected as part of the Alliance phase III trial, C9581.

237 In a multicenter, open-label, phase III trial, elderly patients >/= 70 years old with

238 b (substudy of a larger GSK sponsored global phase III trial, MEA115575) where subjects received mepo

239 d Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) t

240 In one phase III trial, the oral combination of netupitant and

241 In another phase III trial, the oral combination of netupitant and

242 In the ESTIMABL phase III trial, the thyroid ablation rate was equivalen

243 In this open-label phase III trial, we evaluated the safety, tolerability,

244 inating event to clinically definite MS in a phase III trial.

245 vanced melanoma who received ipilimumab in a phase III trial.

246 IB to IV melanoma in a randomized open-label phase III trial.

247 ouble-masked, active-controlled, randomized, phase III trial.

248 patients treated in a randomized, controlled phase III trial.

249 onducted this randomized, placebo-controlled phase III trial.

250 compare the efficacy of these regimens in a phase III trial.

251 mains to be defined by an ongoing randomized phase III trial.

252 ently randomized stratified subgroup of this phase III trial.

253 se II trials were simulated from four actual phase III trials (two positive for OS and two negative f

254 Large Phase III trials across Asia and Latin America have rece

255 Successful phase III trials can lead to approval of a new biologica

256 Phase III trials comparing non-vitamin K antagonist oral

257 act of TILs in primary TNBCs in two adjuvant phase III trials conducted by the Eastern Cooperative On

258 ents using patient-level data merged from 11 phase III trials conducted from 1994 to 2010.

259 However, randomized phase III trials conducted to date have failed to show a

260 om 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherc

261 C435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) inf

262 htly lower as compared to the results of the phase III trials for telaprevir or boceprevir.

263 With the initiation of large phase III trials investigating immunomodulatory drugs fo

264 Phase III trials of buparlisib and endocrine therapy in

265 s for HCC and ICC safely, supporting ongoing phase III trials of radiation in HCC and ICC.

266 ith HER2-positive EBC, providing support for phase III trials of T-DM1 in this setting.

267 Recent placebo-controlled phase III trials of the mammalian target of rapamycin (m

268 logy of dengue viruses (DENV) in two pivotal phase III trials of the tetravalent dengue vaccine, CYD-

269 Most randomized phase III trials on which level-one evidence has been bu

270 Twin phase III trials showed significantly improved survival

271 However, phase III trials testing continuous androgen deprivation

272 se end points in five prospective randomized phase III trials that enrolled a total of 6,081 patients

273 We included patients enrolled onto three phase III trials that randomly assigned patients to nove

274 tcomes, fueling calls for the need for large phase III trials to definitively test this question.

275 Seven published phase III trials were examined for prespecified design a

276 gression, and death obtained from randomized phase III trials were used to determine the likelihood o

277 inform go/no-go decisions for proceeding to phase III trials, and appropriate end points in phase II

278 There are only 2 phase III trials, both on remote ischemic conditioning i

279 remains the most common primary end point of phase III trials, more trials from the last decade have

280 In Phase III trials, rivaroxaban, apixaban, edoxaban (antif

281 LDL-C reduction and that, if proven safe in phase III trials, they will be as important to LDL-C con

282 were pooled from four studies, including two phase III trials, with patients who received nivolumab 3

283 sentative of the participating sites in both Phase III trials.

284 onary embolism, were underrepresented in the Phase III trials.

285 e as that observed in the three EV71 vaccine phase III trials.

286 mains unclear and should be evaluated within phase III trials.

287 s) of action and enhance planning of pivotal Phase III trials.

288 l measures of clinical utility and data from phase III trials.

289 d provides baseline data for planning future phase III trials.

290 pective studies of ipilimumab, including two phase III trials.

291 s of sustained virological response (SVR) in phase III trials.

292 sting that MDT should be explored further in phase III trials.

293 t vaccine Butantan-DV, which is currently in phase III trials.

294 finitions were chosen in accordance with the Phase III trials.

295 b monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 665

296 correlated with reduced HIV-1 infection in a phase III vaccine trial.

297 Recent phase III vaccine trials showed partial protection, and

298 we outline the principal design features of Phase III vector control field studies, highlight major

299 for diabetic macular edema (DME) during the phase III VISTA DME trial were maintained with individua

300 The phase III Zostavax Efficacy and Safety Trial of 1 dose o